The purpose of the study is to see if this treatment can help patients live longer without the cancer coming back. Participants in the study will receive the chemotherapy treatment over a period of 12 months. The study will monitor the patients’ health and check for any signs of the cancer returning. The researchers will also look at how well the treatment works before surgery and how patients respond to the chemotherapy. The study will collect information on any side effects experienced by the participants to ensure the treatment is safe and effective.

Throughout the study, various tests and analyses will be conducted to understand the impact of the treatment on the cancer. This includes looking at specific markers in the cancer cells and analyzing genetic information to see how it might affect the response to the treatment. The study will also involve regular check-ups and assessments to track the overall health and survival of the participants. The goal is to gather valuable information that could lead to better treatment options for patients with this type of cancer in the future.

Participants will receive an injection of the copper‑based agent and then undergo a scan. After a short break, they will receive the standard gallium‑based agent and have a second scan. Doctors will compare the number of tumors seen and a measurement called SUV_MAX, which reflects how bright each tumor appears on the images. The study also includes monitoring for any side effects. The overall time each participant spends in the study is limited to a few visits over several weeks.

The purpose of the study is to check the safety of CRN09682 and to see how well it works in treating these types of cancers. The study has two main parts. In the first part, different amounts of the medication will be tested in small groups of people to find out which dose is safe and appropriate to use. In the second part, a larger group of people will receive the dose that was selected from the first part to learn more about its safety and effectiveness. During the study, doctors will monitor for any side effects and will check how the cancer responds to the treatment.

People joining this study will have regular medical visits where they will receive the study medication and undergo tests to check their health and see how their cancer is responding. The study will look at whether the tumors get smaller, stay the same size, or grow, and will measure how long any positive effects last. Blood samples will be taken to measure the levels of CRN09682 and MMAE in the body. MMAE is a substance that is part of how the medication works against cancer cells. The study will also use special imaging tests that can detect somatostatin receptors to see changes in the tumors over time.

The treatment involves the use of three chemotherapy drugs: etoposide, carboplatin, and cisplatin. These medications are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein. The study will monitor patients over a period of 12 months to assess how well the treatment works in preventing the cancer from returning or spreading. Additionally, the study will collect information on any side effects experienced by patients during the treatment.

Throughout the study, various tests and analyses will be conducted to understand the response of the cancer to the treatment. This includes looking at specific markers in the cancer cells and analyzing genetic information to see if certain characteristics of the cancer can predict how well the treatment will work. The study will also evaluate the overall survival of patients and the feasibility of the treatment regimens. The information gathered from this study will help in understanding the potential benefits of using these chemotherapy drugs in treating localized digestive neuroendocrine carcinomas.

The purpose of the study is to evaluate how effective the 177Lu-DOTATOC treatment is for patients with these types of tumors. The study will follow patients over a period of time to see how their tumors respond to the treatment. Some patients will receive the actual treatment, while others may receive a placebo. The study will also monitor the safety of the treatment by checking for any side effects that occur during and after the treatment period.

Participants in the study will undergo regular assessments to track the progress of their disease and any changes in their quality of life. These assessments will include standard questionnaires and medical imaging tests like MRI or CT scans. The study aims to provide valuable information on the potential benefits and risks of using 177Lu-DOTATOC for treating these specific types of tumors.

The purpose of the study is to determine the appropriate dose of lutetium Lu 177 edotreotide for children, based on its safety and how it moves through the body. The study will involve giving the treatment to participants and monitoring them to see how their bodies respond. This includes checking for any side effects and measuring how the treatment is absorbed by the body. The study will also look at how effective the treatment is in reducing the size of the tumors.

Participants in the study will receive the treatment through an intravenous infusion, which means it will be given directly into a vein. The study will take place over several cycles, with regular check-ups to monitor the participants’ health and the progress of the treatment. The goal is to find the safest and most effective dose for treating these types of tumors in children. The study is expected to continue for several years to gather enough information to make informed decisions about the treatment’s use in the future.

The purpose of this study is to evaluate the safety and effectiveness of these treatments in helping the immune system fight cancer. Participants in the study will receive the treatments over a period of six months. The DC-VACCINE_IRSTIRCCS is given through an injection into the skin, while Proleukin is administered as an injection under the skin. Throughout the study, participants will be monitored for any side effects and changes in their immune response to the cancer.

The study aims to understand how well these treatments work in preventing the return of cancer and improving overall survival. Researchers will also look at how the treatments affect the immune system’s ability to target cancer cells. The study will help determine if these treatments can be a safe and effective option for patients with these rare cancers.

The purpose of this study is to develop new ways to predict how long patients with neuroendocrine neoplasms might remain stable without their disease getting worse. This will be done by analyzing measurements from combined scans using both imaging substances. During the study, participants will receive both types of imaging solutions and undergo PET/CT scanning.

Both imaging substances are given as single injections into a vein. 64Cu-DOTATATE attaches to specific receptors found on neuroendocrine tumors, while 18F-FDG helps show how active the tumor cells are. The combination of these two different types of scans provides doctors with more complete information about the tumor’s characteristics and behavior.

The purpose of this study is to determine whether it is possible to perform both imaging methods at the same time to better understand how tumors use energy. During the study, participants will receive two different injectable substances: hyperpolarized [1-13C]pyruvate and Fluor-18-FDG. Both substances will be given through an intravenous injection, and then special images will be taken using a combined PET/MR scanner.

This research will help doctors better understand how tumors process different nutrients and may lead to improved ways of detecting and monitoring cancer. The imaging procedure will be performed once for each participant, and the total dose of each substance has been carefully calculated to ensure safety.

The study aims to evaluate how well Cabozantinib works in treating this type of cancer. The medication comes in the form of film-coated tablets that are taken by mouth and is available in three different strengths: 20 mg, 40 mg, and 60 mg. The treatment period may last up to 27 months, depending on how well patients respond to the therapy.

During the study, participants will receive Cabozantinib tablets daily. The effectiveness of the treatment will be monitored through regular medical check-ups and imaging tests. Patients will also complete quality of life questionnaires during the course of their treatment. The study will track how the disease responds to the medication and monitor any side effects that may occur.

Participants in this study will be monitored over time to check for any new health issues, particularly focusing on the development of other cancers. The study will also look at any side effects related to the treatment, as well as changes in blood and chemistry tests. Additionally, the study will track the overall survival of participants, which means observing the time from when they first received the treatment until any cause of death.

This study is part of a larger effort to ensure the safety of treatments for neuroendocrine tumors and to better understand the long-term effects of using 177Lu-IPN01072. By gathering this information, researchers hope to improve future treatment options and provide better care for patients with this type of cancer.

Participants in the study will be randomly assigned to receive either the dosimetry-based PRRT or the standard dose PRRT. Throughout the study, patients will undergo various tests and scans to monitor their health and the effects of the treatment. The study aims to compare the outcomes of the two different dosing methods, including how long patients live without their disease getting worse, the amount of radiation the tumor receives, and any side effects experienced, particularly those affecting the kidneys and bone marrow.

The study will also look at how the treatment affects the overall well-being of the patients, including any subjective side effects they might experience. The goal is to determine if tailoring the dose of 177Lu-DOTATOC based on individual needs can improve treatment outcomes and reduce side effects for patients with Neuroendocrine Tumor.

The purpose of the study is to evaluate how effective two additional cycles of Lutathera are in patients who have already received a similar treatment in the past and are experiencing new tumor growth. Participants will receive one infusion every two months, and the study will compare this treatment to a period of active monitoring without additional treatment. The study will last for several months, and participants will have regular check-ups to monitor their health and the progress of the treatment.

Throughout the study, participants will undergo various assessments, including imaging tests like MRI or CT scans, to measure the size and growth of the tumors. The study aims to determine the rate of disease control, which includes complete or partial response to the treatment or stable disease. Safety and quality of life will also be evaluated using standard questionnaires. The trial is expected to continue for several years, with the goal of improving treatment options for patients with neuroendocrine tumors.

Participants in the study will receive either Lutathera in combination with supportive care or a higher dose of Sandostatin LAR. Lutathera is administered through an intravenous infusion, which means it is given directly into a vein, while Sandostatin LAR is given as an intramuscular injection, meaning it is injected into a muscle. The study will also involve the use of a solution called LysaKare, which contains L-lysine hydrochloride and L-arginine hydrochloride, to help protect the kidneys during treatment. The trial will follow participants over a period to observe the time it takes for the disease to progress or for any other significant health changes to occur.

The study is designed to be open-label, meaning both the participants and the researchers know which treatment is being administered. It is a randomized trial, which means participants are randomly assigned to receive either Lutathera or the higher dose of Sandostatin LAR. The trial will take place across multiple centers, allowing for a diverse group of participants. The ultimate goal is to gather information that could lead to improved treatment options for patients with advanced GEP-NETs.

The purpose of the study is to evaluate how safe Lutathera is for use in adolescents and to understand how the body absorbs the radiation from this treatment. Another medication used in the study is called LysaKare, which contains L-lysine hydrochloride and L-arginine hydrochloride. These are amino acids that help protect the kidneys during the treatment. The study will involve monitoring the participants over a period of time to see how their bodies respond to the treatment and to check for any side effects.

Participants in the study will receive the treatment over a period of up to 36 months. During this time, doctors will closely monitor the participants’ health and the effects of the treatment. The study aims to gather information on the safety and effectiveness of Lutathera in treating these specific types of tumors in adolescents. This information will help in understanding how well the treatment works and its potential side effects.

The purpose of this study is to understand how the continued use of long-acting somatostatin analogs affects the amount of radiation absorbed by the tumor during a treatment called Peptide Receptor Radionuclide Therapy (PRRT). PRRT is a type of therapy that uses a small amount of radioactive material to target and kill cancer cells. The study will involve administering these medications to patients and monitoring the effects on their tumors over a period of time. The medications will be given through injections, with Octreotide administered intramuscularly, Lanreotide subcutaneously, and Lutetium (177Lu) Oxodotreotide intravenously.

Throughout the study, patients will undergo imaging tests to measure the radiation absorbed by the tumors and other tissues in the body. These tests will help researchers understand how the treatment affects both the cancer and the surrounding healthy tissues. The study aims to provide valuable insights into the effectiveness and safety of using these medications together in treating neuroendocrine tumors.

The purpose of the study is to understand the benefits of continuing treatment with somatostatin analogues (a type of medication that helps control hormone-related symptoms) when the disease progresses. The study is divided into two parts: one part looks at the effects of continuing or stopping these medications when patients start a second-line treatment called PRRT (Peptide Receptor Radionuclide Therapy), and the other part examines the effects when patients start a different type of second-line treatment known as targeted therapy. The study aims to see if continuing these medications can help delay the worsening of the disease and improve the quality of life for patients.

Participants in the study will receive either the medication or a placebo, and their progress will be monitored over time. The study will assess how long patients can live without their disease getting worse and how long it takes for their overall health to decline. The study will also look at the overall survival rates, response to treatment, quality of life, and any side effects experienced by the participants. This information will help determine the best approach to managing neuroendocrine tumors when the disease progresses.

Participants in the study will receive either 177Lu-Edotreotide or Afinitor. 177Lu-Edotreotide is given through an intravenous infusion, which means it is delivered directly into the bloodstream. Afinitor is taken orally as a tablet. The study will also include a group of participants who will receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments. The study will last for a period of time, during which participants will be monitored regularly to assess the progression of their disease and any side effects they may experience.

The main goal of the study is to determine how long the treatments can prevent the cancer from progressing, which is known as progression-free survival. This will be measured from the time participants start the study until their disease shows signs of getting worse or they pass away. The study will also collect information on how the treatments impact the participants’ daily lives and overall well-being. This information will help doctors understand which treatment might be more beneficial for patients with neuroendocrine tumors of the lung and thymus.

The purpose of the study is to compare the effectiveness and safety of personalized versus non-personalized radionuclide therapy using 177Lu-Edotreotide in patients with neuroendocrine tumors. Participants in the study will receive either a personalized or non-personalized treatment plan. The study will monitor the progress of the disease and any side effects experienced by the participants. The treatment period can last up to 36 months for 177Lu-Edotreotide and up to 48 months for Capecitabine.

Throughout the study, participants will undergo regular assessments to track the progression of their disease and to evaluate the impact of the treatment. These assessments may include imaging tests like MRI or CT scans to visualize the tumors. The study aims to provide valuable information on how these treatments can be used to improve outcomes for patients with neuroendocrine tumors.